As Covid pro­gram ad­vances, Enan­ta's new CMO says it's not 'lim­it­ed to an­tivi­ral­s'; With all eyes on Gilead-part­nered can­cer drugs, Ar­cus brings med­ical chief on board

Ex­pect some pipeline ad­just­ments at Enan­ta Phar­ma­ceu­ti­cals in the com­ing years, be­cause new CMO Scott Rot­ting­haus thinks the an­tivi­ral biotech can ex­pand its hori­zons while al­so fig­ur­ing out a way to ad­dress the years­long Covid pan­dem­ic with an ex­pect­ed Phase II launch lat­er this year.

“I would like to take a look at what we have as pos­si­bil­i­ties com­ing out of the lab. We have such a strong dis­cov­ery pro­gram,” Rot­ting­haus told End­points News. “I don’t think we need to be lim­it­ed to an­tivi­rals here at Enan­ta; we can take a broad­er look at some oth­er ther­a­peu­tic ar­eas.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.